| 23.65 1.35 (6.05%) | 04-23 13:46 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 30.48 |
1-year : | 35.6 |
| Resists | First : | 26.1 |
Second : | 30.48 |
| Pivot price | 23.87  |
|||
| Supports | First : | 22.84 |
Second : | 20.84 |
| MAs | MA(5) : | 22.98 |
MA(20) : | 24.22 |
| MA(100) : | 24.92 |
MA(250) : | 25.89 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 33.5 |
D(3) : | 18.1 |
| RSI | RSI(14): 51 |
|||
| 52-week | High : | 34.27 | Low : | 20.84 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CORT ] has closed below upper band by 46.6%. Bollinger Bands are 18% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 22.82 - 22.93 | 22.93 - 23.04 |
| Low: | 20.53 - 20.66 | 20.66 - 20.79 |
| Close: | 22.04 - 22.26 | 22.26 - 22.48 |
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
Tue, 23 Apr 2024
Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study - Zacks Investment Research
Mon, 22 Apr 2024
Corcept Therapeutics (NASDAQ:CORT) Sets New 52-Week Low at $20.84 - MarketBeat
Mon, 22 Apr 2024
Mid-Cap Corcept Therapeutics Reveals Data From Hormonal Disorder Study, FDA Application Submission Expect - Benzinga
Mon, 22 Apr 2024
Corcept falls after phase 3 results on Cushing's candidate doesn't include some data - Seeking Alpha
Mon, 22 Apr 2024
Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With ... - Markets Insider
Fri, 19 Apr 2024
Cerity Partners LLC Decreases Stock Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 104 (M) |
| Shares Float | 85 (M) |
| Held by Insiders | 11.4 (%) |
| Held by Institutions | 86.1 (%) |
| Shares Short | 21,330 (K) |
| Shares Short P.Month | 19,860 (K) |
| EPS | 0.93 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.9 |
| Profit Margin | 22 % |
| Operating Margin | 23.3 % |
| Return on Assets (ttm) | 11.1 % |
| Return on Equity (ttm) | 21 % |
| Qtrly Rev. Growth | 31.3 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 4.64 |
| EBITDA (p.s.) | 1.04 |
| Qtrly Earnings Growth | 99.5 % |
| Operating Cash Flow | 127 (M) |
| Levered Free Cash Flow | 128 (M) |
| PE Ratio | 25.55 |
| PEG Ratio | -0.6 |
| Price to Book value | 4.9 |
| Price to Sales | 5.17 |
| Price to Cash Flow | 19.63 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|